Blood Proteins Patents (Class 435/69.6)
-
Publication number: 20140356908Abstract: A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization.Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: ERASMUS UNIVERSITY MEDICAL CENTERInventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS
-
Publication number: 20140356362Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: ApplicationFiled: August 13, 2014Publication date: December 4, 2014Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
-
Publication number: 20140357521Abstract: The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.Type: ApplicationFiled: January 21, 2013Publication date: December 4, 2014Inventors: Jan Steyaert, Nico Callewaert, Toon Laeremans, Els Pardon, Kristof Vandewalle, Katrien Claes
-
Publication number: 20140356376Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20140356907Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: ERASMUS UNIVERSITY MEDICAL CENTERInventors: FRANKLIN GERARDUS GROSVELD, RICHARD WILHELM JANSSENS, MARINUS JOHANNES VAN HAPEREN, ROGER KINGDON CRAIG, ERNIE DE BOER
-
Publication number: 20140356911Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.Type: ApplicationFiled: July 29, 2014Publication date: December 4, 2014Applicant: UCB PHARMA S.A.Inventor: Katharine Lacy Cain
-
Publication number: 20140356381Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.Type: ApplicationFiled: March 14, 2014Publication date: December 4, 2014Applicant: Xencor, Inc.Inventors: Gregory Moore, Matthew Bernett, John Desjarlais
-
Publication number: 20140356326Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: December 10, 2013Publication date: December 4, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Publication number: 20140356910Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.Type: ApplicationFiled: May 29, 2014Publication date: December 4, 2014Applicant: AMGEN INC.Inventors: Chung-Jr HUANG, Xiaoming YANG
-
Publication number: 20140356909Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.Type: ApplicationFiled: April 28, 2014Publication date: December 4, 2014Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
-
Publication number: 20140357564Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.Type: ApplicationFiled: February 14, 2013Publication date: December 4, 2014Inventors: Stefan Schulte, Thomas Weimer, Kay Hofmann
-
Publication number: 20140356358Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.Type: ApplicationFiled: December 17, 2012Publication date: December 4, 2014Inventors: Jeonghoon Sun, Seog Joon Han, Susie M. Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
-
Publication number: 20140357565Abstract: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-a (CHEF1) promoter, which may be used in the methods provided herein.Type: ApplicationFiled: August 13, 2014Publication date: December 4, 2014Inventors: Randal J. KAUFMAN, Steven W. Pipe, Michael GRIFFITH
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8901280Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.Type: GrantFiled: October 25, 2007Date of Patent: December 2, 2014Assignee: Gene Techno Science Co., Ltd.Inventors: Shigeyuki Kon, Chiemi Kimura, Toshimitsu Uede
-
Publication number: 20140348745Abstract: The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.Type: ApplicationFiled: December 12, 2012Publication date: November 27, 2014Inventors: Roy H. Larsen, Jostein Dahle
-
Publication number: 20140348826Abstract: The invention relates generally to a new trimerization domain useful for developing multifunctional and multivalent complexes. Particularly, the invention relates to the design of trimeric polypeptide complexes using polypeptide structural elements derived from the collagen XV protein, and their use in diagnostic and therapeutic systems in vivo and in vitro. The invention also relates to nucleic acids and vectors useful for producing said trimeric complexes.Type: ApplicationFiled: August 22, 2011Publication date: November 27, 2014Applicant: LEADARTIS, S.L.Inventors: Luis Álvarez Vallina, Ángel Cuesta-Martínez, Noelia Sainz Pastor, Laura Sanz Alcober
-
Publication number: 20140348837Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: November 15, 2012Publication date: November 27, 2014Applicants: Amegen Research (Munich) GmbH, Boehringer Ingellheim iInternational GmbhInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20140350225Abstract: Disclosed are an anti-bFGF humanized double-stranded antibody with stable disulfide bond, the preparation method and the applications thereof. The amino acid sequence of the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 1. The nucleotide sequence of gene encoding the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 2. By site-directed mutation, two cysteine residues are introduced into each single-stranded antibody, thus introducing the disulfide bond and form ds-Diabody. It is shown by experiments that the obtained ds-Diabody has the following advantages: enhanced stability; better affinity when binding to the specific antigen bFGF; moderate relative molecular weight, good tumor targeting, more powerful in tumor tissue penetration, and higher blood clearance rate, showing a broad application prospects in the clinic diagnosis and tumor therapy.Type: ApplicationFiled: August 20, 2012Publication date: November 27, 2014Applicant: JINAN UNIVERSITYInventors: Ning Deng, Haowu Jiang, Zhongkui Kang, Hong Wang, Qifang Song
-
Publication number: 20140348841Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: ApplicationFiled: April 24, 2014Publication date: November 27, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Publication number: 20140348820Abstract: The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.Type: ApplicationFiled: April 29, 2014Publication date: November 27, 2014Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, NOVARTIS AGInventors: Naresh CHENNAMSETTY, Bernhard HELK, Veysel KAYSER, Bernhardt TROUT, Vladimir VOYNOV
-
Publication number: 20140348839Abstract: The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.Type: ApplicationFiled: December 18, 2012Publication date: November 27, 2014Inventors: Partha S. Chowdhury, Vaheh Oganesyan, Yariv Mazor, Nazzareno Dimasi
-
Publication number: 20140349342Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.Type: ApplicationFiled: April 23, 2014Publication date: November 27, 2014Applicant: Ablynx N.V.Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
-
Publication number: 20140343258Abstract: [Problem] An object of the present invention is to provide an anti-human CTGF antibody having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, and means for preventing or treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy, using the anti-human CTGF antibody. [Means for Solution] An anti-human CTGF antibody includes: a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 10; and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 4.Type: ApplicationFiled: December 21, 2012Publication date: November 20, 2014Applicant: ASTELLAS PHARMA INC.Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
-
Publication number: 20140342405Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20140341903Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.Type: ApplicationFiled: October 1, 2012Publication date: November 20, 2014Applicant: Ablynx N.V.Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
-
Publication number: 20140343267Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.Type: ApplicationFiled: April 24, 2014Publication date: November 20, 2014Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140342406Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.Type: ApplicationFiled: May 23, 2014Publication date: November 20, 2014Applicant: UCB PHARMA S.A.Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
-
Publication number: 20140341906Abstract: The present invention features inter alia polypeptides comprising heterodimeric Fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject.Type: ApplicationFiled: July 13, 2012Publication date: November 20, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Frederick R. Taylor, Justin A. Caravella, Alexey A. Lugovskoy, Amna Saeed-Kothe, Ellen A. Garber
-
Publication number: 20140341917Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.Type: ApplicationFiled: November 21, 2012Publication date: November 20, 2014Applicant: MERCK PATENT GMBHInventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
-
Publication number: 20140341910Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: November 26, 2013Publication date: November 20, 2014Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20140343252Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: November 20, 2014Applicant: Amgen Inc.Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
-
Publication number: 20140342404Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.Type: ApplicationFiled: April 10, 2013Publication date: November 20, 2014Applicant: GENENTECH, INC.Inventor: Leonard G. PRESTA
-
Publication number: 20140342407Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose, Marie Pancera
-
Patent number: 8889374Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.Type: GrantFiled: December 23, 2010Date of Patent: November 18, 2014Assignee: University Court of the University of EdinburghInventors: Christoph Schmidt, Paul N. Barlow, Anna Richards
-
Publication number: 20140335565Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.Type: ApplicationFiled: August 1, 2014Publication date: November 13, 2014Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama
-
Publication number: 20140336363Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
-
Publication number: 20140335014Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 8, 2014Publication date: November 13, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
-
Publication number: 20140335564Abstract: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.Type: ApplicationFiled: April 22, 2014Publication date: November 13, 2014Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
-
Publication number: 20140335107Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: March 19, 2014Publication date: November 13, 2014Applicant: GENENTECH, INC.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Publication number: 20140335101Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: February 27, 2014Publication date: November 13, 2014Applicant: Ablynx N.V.Inventor: Els Anna Alice Beirnaert
-
Publication number: 20140335563Abstract: It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.Type: ApplicationFiled: March 28, 2014Publication date: November 13, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuaki TAKAHASHI, Hideaki YOSHIDA
-
Publication number: 20140335091Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.Type: ApplicationFiled: May 2, 2014Publication date: November 13, 2014Applicant: RINAT NEUROSCIENCE CORP.Inventors: Alison Jane FORGIE, Javier Fernando CHAPARRO RIGGERS, Edward Roland LAVALLIE, Chia-Yang LIN, Lidia MOSYAK, Andrea ROSSI, Thomas John VAN BLARCOM
-
Publication number: 20140335609Abstract: The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfeType: ApplicationFiled: June 2, 2014Publication date: November 13, 2014Applicant: Hoffmann-La Roche Inc.Inventors: ULRICH GOEPFERT, Hendrik Knoetgen, Erhard Kopetzki, Anne Stern
-
Publication number: 20140335089Abstract: The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fc?-receptor-binding domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fc? receptor-binding domain has higher binding activity to the Fc? receptor in a neutral pH range condition than an Fc region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain.Type: ApplicationFiled: September 28, 2012Publication date: November 13, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana
-
Patent number: 8883992Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.Type: GrantFiled: October 26, 2012Date of Patent: November 11, 2014Assignee: Medimmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Publication number: 20140329276Abstract: Methods for increasing the yield and N-glycosylation site occupancy of paucimannose or complex N-glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl alpha-1,3 mannosyltransferase (Alg3p) activity are disclosed. In particular, recombinant host cells are provided that comprise a disruption of the expression of an OS-9 family gene in the host cell. These recombinant host cells may then be used for producing recombinant glycoproteins. In further embodiments, the recombinant host cells further overexpress at least one heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex.Type: ApplicationFiled: October 23, 2012Publication date: November 6, 2014Applicant: MERCK SHARP & DOHME CORP.Inventors: Byung-Kwon Choi, Stephen R. Hamilton, Natarajan Sethuraman
-
Publication number: 20140329277Abstract: The invention concerns a method for culturing cells in order to produce substances. According to the invention a cell line producing substances is cultured while feeding a nutrient medium in such a manner that glucose limitation occurs in the culture solution. The degree of glucose limitation DGL=qGlc/qGlcmax (qGlc=observed current specific glucose consumption rate; qGlcmax=maximum known specific glucose consumption rate for these cells). DGL is between the limits 0 and 1, where 0 means complete limitation and 1 means no limitations or complete glucose excess. According to the invention DGL is larger or equal to the DGL which only leads to the maintenance of the cell and ?0.5.Type: ApplicationFiled: January 21, 2014Publication date: November 6, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Thomas Link, Ruth Essers, Kerstin Zorner, Jochen Gatgens, Thomas Noll, Christian Wandrey
-
Publication number: 20140328850Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.Type: ApplicationFiled: July 17, 2012Publication date: November 6, 2014Inventors: Shu-Chen Lu, Minghan Wang